Radiopharm Theranostics Ltd (RDPTF)
RDPTF is quoted over the counter, not listed on an exchange. Radiopharm Theranostics Ltd files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.
Closes: Yahoo Finance daily closes, last bar 2026-11-13.
Profile
| Field | Value |
|---|---|
| Ticker | RDPTF, quoted over the counter |
| SEC CIK | 0001949257 |
| OTC Markets tier | Pink (price source, 2026-11-13) |
| SEC industry code | Pharmaceutical Preparations |
| Business address | Carlton Vic |
| Incorporated in | Australia |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions, along with other matters as set forth in Note 20(a)(iii), raise substantial doubt about the Group's ability to continue as a going concern." | 20-F 2026-09-30 |
| Cash and burn | $4.1M cash; operating cash flow -$13.2M a quarter. | Report 2026-06-30 |
| Shares outstanding | No cover-page share count in XBRL | Cover page 2026-06-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 3 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the market | Latest 2026-07-27 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Grant Thornton Audit Pty Ltd, Melbourne, Australia | PCAOB Form AP 2026-10-08 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2026 2026-06-30 | $2.8M | -$57.0M | -$52.8M | $4.1M | No debt tags | $2.8M | 20-F 2026-09-30 |
| FY 2025 2025-06-30 | $3.6M | -$38.3M | -$36.6M | $29.1M | No debt tags | $3.6M | 20-F 2025-09-18 |
| FY 2024 2024-06-30 | $299K | -$47.9M | -$23.0M | $18.6M | No debt tags | $299K | 20-F 2025-09-18 |
| FY 2023 2023-06-30 | $292K | -$34.6M | -$23.2M | $11.7M | No debt tags | $292K | 20-F 2025-09-18 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-09-23 |
| Latest annual report | 20-F | 2026-09-30 |
| Latest quarterly / interim | 6-K | 2026-11-16 |
Source: SEC EDGAR submissions feed, 166 recent filings. All filings on EDGAR.
The full dossier has every filing, quarterly and annual financials, the health record and a price chart.
Open the full dossier